Cosmo Pharmaceuticals N.V. (CMOPF) Research

Cosmo Pharmaceuticals N.V. operates as a specialized pharmaceutical enterprise, globally dedicated to the research, development, and commercialization of products primarily focused on gastroenterology and endoscopy. Its diverse product portfolio includes Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, oral tablet formulations crucial for achieving remission in individuals with active, mild to moderate ulcerative colitis. In the realm of diagnostics, the company provides GI Genius, an AI-powered system designed to enhance the detection of colorectal polyps, alongside Methylene Blue MMX, a diagnostic medication that improves the visibility of pre-cancerous and cancerous colorectal lesions during colonoscopic procedures. For endoscopic interventions, Eleview offers an injectable compound utilized for the submucosal lift of various gastrointestinal mucosal abnormalities, such as polyps, adenomas, or early-stage cancers. Cosmo's therapeutic offerings also feature Aemcolo/Relafalk, a pharmaceutical agent addressing traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth. Expanding its reach into dermatology, the company markets Winlevi, an androgen receptor inhibitor for acne vulgaris, and Clascoterone, another androgen receptor inhibitor specifically formulated for androgenetic alopecia affecting the scalp. Further products and pipeline candidates encompass Rifamycin for irritable bowel syndrome with diarrhea, ByFavo (Remimazolam) as a rapid-acting intravenous benzodiazepine for procedural sedation, CB-03-10—an oral androgen receptor antagonist targeting solid tumors, CB-01-33 for bile acid diarrhea, and Qolotag, a single-use enema preparation. The firm maintains licensing collaborations with RedHill Biopharma Ltd. and Acacia Pharma Group plc. Founded in 1997, Cosmo Pharmaceuticals N.V. maintains its corporate headquarters in Dublin, Ireland.

Open Cosmo Pharmaceuticals N.V. (CMOPF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.